Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
09:30am, Saturday, 18'th Oct 2025
Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and M
Moderna, Inc. (MRNA) Shareholder/Analyst Call Transcript
04:06pm, Friday, 17'th Oct 2025
Moderna, Inc. (NASDAQ:MRNA ) Shareholder/Analyst Call October 17, 2025 12:00 PM EDT Company Participants Kyle Holen Lavina Talukdar - Senior VP & Head of Investor Relations Conference Call Participant
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
07:00am, Thursday, 16'th Oct 2025
CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to r
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
06:51pm, Tuesday, 14'th Oct 2025
In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.
Moderna: Q3 Earnings Preview - I Fear A Halloween Horror Show (Downgrade)
04:57pm, Tuesday, 14'th Oct 2025
Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients
10:52am, Monday, 13'th Oct 2025
Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkp
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety an
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Wednesday, 08'th Oct 2025
In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Monday, 06'th Oct 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know
06:51pm, Thursday, 02'nd Oct 2025
Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
11:36am, Thursday, 02'nd Oct 2025
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
10:31am, Thursday, 02'nd Oct 2025
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short
2 Beaten-Down Stocks to Buy and Hold for a Decade
07:30am, Tuesday, 30'th Sep 2025
Over the past couple of years, Moderna (MRNA 3.39%) and Regeneron Pharmaceuticals (REGN -0.62%) have encountered company-specific headwinds that have sunk their stock prices. The former is down by 75%
3 Of My Favorite Biotech Stocks Under $10
01:15pm, Monday, 29'th Sep 2025
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
12:37pm, Thursday, 25'th Sep 2025
Moderna, Inc. (NASDAQ:MRNA ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice Pre
